Signaling networks associated with AKT activation in non-small cell lung cancer (NSCLC): New insights on the role of phosphatydil-inositol-3 kinase

PLoS ONE

Volumn 7, Issue 2, 2012, Pages

  Scrima, Marianna ^a   de Marco, Carmela ^a,b   Fabiani, Fernanda ^b   Franco, Renato ^c   Pirozzi, Giuseppe ^c   Rocco, Gaetano ^c   Ravo, Maria ^d   Weisz, Alessandro ^d   Zoppoli, Pietro ^a,e   Ceccarelli, Michele ^a,e   Botti, Gerardo ^c   Malanga, Donatella ^a,b   Viglietto, Giuseppe ^a,b  

^a Grande Ospedale Metropolitano   (Italy)

^b UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d UNIVERSITY OF SALERNO   (Italy)

^e UNIVERSITY OF SANNIO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; KRAS PROTEIN, HUMAN; ONCOPROTEIN; PHOSPHOSERINE; PTEN PROTEIN, HUMAN; RAS PROTEIN; TUMOR PROTEIN;

ADULT; AGED; AKT1 GENE; AKT2 GENE; ALLELE; ARTICLE; CANCER GRADING; CANCER INHIBITION; CONTROLLED STUDY; COPY NUMBER VARIATION; DISEASE ASSOCIATION; DNA SEQUENCE; ENZYME ACTIVATION; ENZYME ACTIVITY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOS GENE; GENE EXPRESSION PROFILING; GENE LOSS; GENE REGULATORY NETWORK; GENETIC ASSOCIATION; HMGA1 GENE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MALE; MOLECULAR PATHOLOGY; MUTATIONAL ANALYSIS; ONCOGENE; ONCOGENE K RAS; ONCOGENE MYC; P110ALPHA GENE; PROTEIN EXPRESSION; PTEN GENE; SIGNAL TRANSDUCTION; TISSUE MICROARRAY; TRANSCRIPTION REGULATION; CELL PROLIFERATION; CELL TRANSFORMATION; ENZYMOLOGY; EPITHELIUM CELL; GENE EXPRESSION REGULATION; GENETICS; LUNG TUMOR; METABOLISM; MIDDLE AGED; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PATHOLOGY; TUMOR CELL LINE;

ADULT; AGED; AGED, 80 AND OVER; BASE SEQUENCE; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; DNA MUTATIONAL ANALYSIS; ENZYME ACTIVATION; EPITHELIAL CELLS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; NEOPLASM PROTEINS; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHOSERINE; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; RAS PROTEINS; SIGNAL TRANSDUCTION;

EID: 84857164614     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0030427     Document Type: Article

References (57)

1. Hecht SS, (1999) Tabacco smoke carcinogens and Lung cancer. J Natl Cancer Inst 91: 1194-210.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. (2008) Cancer statistics, 2008 CA Cancer. J Clin 58: 71-96.
3. Hirsh FR, Corrin B, Colby TV, (2004) Tumours of the lung. Clinical features and staging. In: Travis WD, Brambilla E, Muller-Her- melink E, Harris CC, editors. WHO Classification, Tumours of the Lung, Pleura, Thymus and Heart Lyon IARC Press pp. 16-19.
4. Minna JD, Roth JA, Gazdar AF, (2002) Focus on lung cancer. Cancer Cell 1: 49-52.
5. Mountain CF, (2000) The international system for staging lung cancer. Semin Surg Oncol 18: 106-15.
6. Vivanco I, Sawyers CL, (2002) The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev cancer 2: 489-501.
7. Altomare DA, Testa JR, (2005) Perturbations of the AKT signaling pathway in human cancer. Oncogene 24: 7455-64.
8. Carnero A, (2010) The PKB/AKT pathway in cancer. Curr Pharm Des 16: 34-44.
9. Memmott RM, Dennis PA, (2010) The role of the Akt/mTOR pathway in tobacco carcinogen-induced lung tumorigenesis. Clin Cancer Res 16: 4-10.
10. Xu CX, Jin H, Shin JY, (2010) Roles of protein kinase B/Akt in lung cancer. Front Biosci 2: 1472-84.
11. Vanhaesebroeck B, Waterfield MD, (1999) Signaling by distinct classes of phosphoinositide 3-kinases. Exp Cell Res 253: 239-54.
12. Datta SR, Brunet A, Greenberg ME, (1999) Cellular survival: a play in three Akts. Genes Dev 13: 2905-27.
13. Hanada M, Feng J, Hemmings BA, (2004) Structure, regulation and function of PKB/AKT-a major therapeutic target. Biochim Biophys Acta 1697: 3-16.
14. Di Cristofano A, Pandolfi PP, (2000) The multiple roles of PTEN in tumour suppression. Cell 100: 387-90.
15. Massion PP, Kuo WL, Stokoe D, Olshen AB, Treseler PA, et al. (2002) Genomic copy number analysis of non-small cell lung cancer using array comparative genomic hybridization: implications of the phosphatidylinositol 3-kinase pathway. Cancer Res; 62: 3636-40.
16. Brognard J, Clark AS, Ni Y, Dennis PA, (2001) Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res 61: 3986-97.
17. Kurie JM, (2004) Role of protein kinase B-dependent signaling in lung tumorigenesis. Chest 125: 141S-144S.
18. Tsao AS, McDonnell T, Lam S, Putnam JB, Bekele N, et al. (2003) Increased phospho-AKT (Ser(473)) expression in bronchial dysplasia: Implications for lung cancer prevention studies. Cancer Epidemiol Biomarkers Prev 12: 660-4.
19. Balsara BR, Pei J, Mitsuuchi Y, Page R, Klein-Szanto A, et al. (2004) Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions. Carcinogenesis 25: 2053-9.
20. Tsurutani J, Fukuoka J, Tsurutani H, Shih JH, Hewitt SM, et al. (2006) Evaluation of two phosphorylation sites improves the prognostic significance of Akt activation in non-small-cell lung cancer tumours. J Clin Oncol 24: 306-14.
21. Tang JM, He QY, Guo RX, Chang XJ, (2006) Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis. Lung Cancer 51: 181-91.
22. Lim WT, Zhang WH, Miller CR, Watters JW, Gao F, et al. (2007) PTEN and phosphorylated AKT expression and prognosis in early- and late-stage non-small cell lung cancer. Oncol Rep 17: 853-7.
23. Rimm DL, Camp RL, Charette LA, Costa J, Olsen DA, et al. (2001) Tissue microarray: a new technology for amplification of tissue resources. Cancer J 7: 24-31.
24. Malanga D, Scrima M, De Marco C, Fabiani F, De Rosa N, et al. (2008) Activating E17K mutation in the gene encoding the protein kinase AKT1 in a subset of squamous cell carcinoma of the lung. Cell Cycle 7: 665-9.
25. Rychahou PG, Kang J, Gulhati P, Doan HQ, Chen LA, et al. (2008) Akt2 overexpression plays a critical role in the establishment of colorectal cancer metastasis. Proc Natl Acad Sci U S A 105: 20315-20.
26. Aziz SA, Davies M, Pick E, Zito C, Jilaveanu L, et al. (2009) Phosphatidylinositol-3-kinase as a therapeutic target in melanoma. Clin Cancer Res 15: 3029-36.
27. Carvalho S, Milanezi F, Costa JL, Amendoeira I, Schmitt F, (2010) PIKing the right isoform: the emergent role of the p110beta subunit in breast cancer. Virchows Arch 456: 235-43.
28. Liu JF, Zhou XK, Chen JH, Yi G, Chen HG, et al. (2010) Up-regulation of PIK3CA promotes metastasis in gastric carcinoma. World J Gastroenterol 16: 4986-91.
29. Lin Y, Jiang X, Shen Y, Li M, Ma H, et al. (2009) Frequent mutations and amplifications of the PIK3CA gene in pituitary tumours. Endocr Relat Cancer 16: 301-10.
30. Lee SH, Kim HS, Park WS, Kim SY, Lee KY, et al. (2002) Non-small cell lung cancers frequently express phosphorylated Akt; an immunohistochemical study. APMIS 110: 587-92.
31. Loupakis F, Pollina L, Stasi I, Ruzzo A, Scartozzi M, et al. (2009) PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. J Clin Oncol 27: 2622-9.
32. Wang G, Kang C, Pu P, (2010) Increased expression of Akt2 and activity of PI3K and cell proliferation with the ascending of tumor grade of human gliomas. Clin Neurol Neurosurg 112: 324-7.
33. Kirkegaard T, Witton CJ, Edwards J, Nielsen KV, Jensen LB, et al. (2010) Molecular alterations in AKT1, AKT2 and AKT3 detected in breast and prostatic cancer by FISH. Histopathology 56: 203-11.
34. Abubaker J, Bavi P, Al-Haqawi W, Jehan Z, Munkarah A, et al. (2009) PIK3CA alterations in Middle Eastern ovarian cancers. Mol Cancer 8: 51.
35. Sambrook J, Fritsch EF, Maniatis T, (1992) Molecular Cloning: A Laboratory Manual 2 New York Cold Spring Harbor Laboratory Press.
36. Chomczynski P, Sacchi N, (1987) Single-step method of RNA from isolated by acid guanidinium thiocyanate-phenol-chlorophorm extraction. Anal Biochem 162: 156-9.
37. Livak KJ, Schmittgen TD, (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-8.
38. Amodio N, Scrima M, Palaia L, Salman AN, Quintiero A, et al. (2010) Oncogenic role of the E3 ubiquitin ligase NEDD4-1, a PTEN negative regulator, in non-small-cell lung carcinomas. Am J Pathol 177: 2622-34.
39. Reddel RR, Ke Y, Gerwin BI, McMenamin MG, Lechner JF, et al. (1988) Transformation of human bronchial epithelial cells by infection with SV40 or adenovirus-12 SV40 hybrid virus, or transfection via strontium phosphate coprecipitation with a plasmid containing SV40 early region genes. Cancer Res 48: 1904-9.
40. Zufferey R, Donello JE, Hope TJ, (1997) Woodchuck hepatitis virus posttranscriptional regulatory element enhances expression of transgenes delivered by retroviral vectors. J Virol 73: 2886-92.
41. Benjamini Y, Hochberg Y, (1995) Controlling the false discovery rate-a practical and powerful approach to multiple testing. J R Stat Soc Ser B 57: 289-300.
42. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, et al. (2004) High Frequency of Mutations of the PIK3CA Gene in Human Cancers. Science 304: 554.
43. Wang Y, Hou P, Yu H, Wang W, Ji M, et al. (2007) High prevalence and mutual exclusivity of genetic alterations in the phosphatidylinositol-3-kinase/Akt pathway in thyroid tumours. J Clin Endocrinol Metab 92: 2387-90.
44. Wu G, Mambo E, Guo Z, Hu S, Huang X, et al. (2005) Uncommon mutation, but common amplifications, of the PIK3CA gene in thyroid tumours. J Clin Endocrinol Metab 90: 4688-93.
45. Kawano O, Sasaki H, Okuda K, Yukiue H, Yokoyama T, et al. (2007) PIK3CA gene amplification in Japanese non-small cell lung cancer. Lung Cancer 58: 159-60.
46. Riely GJ, Marks J, Pao W, (2009) KRAS mutations in non-small cell lung cancer. Proc Am Thorac Soc 6: 201-5.
47. Rodenhuis S, Slebos RJ, Boot AJ, Evers SG, Mooi WJ, et al. (1988) Incidence and possible clinical significance of K-ras oncogene activation in adenocarcinoma of the human lung. Cancer Res 48: 5738-41.
48. Chalhoub N, Baker SJ, (2009) PTEN and the PI3-kinase pathway in cancer. Annu Rev Pathos 4: 127-50.
49. Yamamoto H, Shigematsu H, Nomura M, Lockwood WW, Sato M, et al. (2008) PIK3CA mutations and copy number gains in human lung cancers. Cancer Res 68: 6913-21.
50. Endoh H, Yatabe Y, Kosaka T, Kuwano H, Mitsudomi T, (2006) PTEN and PIK3CA expression is associated with prolonged survival after gefitinib treatment in EGFR-mutated lung cancer patients. J Thorac Oncol 1: 629-34.
51. Marks JL, McLellan MD, Zakowski MF, (2007) Mutational analysis of EGFR and related signaling pathway genes in lung adenocarcinomas identifies a novel somatic kinase domain mutation in FGFR4. PLoS One 2: e426.
52. Gandhi J, Zhang J, Xie Y, Soh J, Shigematsu H, et al. (2009) Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines. PLoS One 4: e4576.
53. Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, Neve RM, Kuo WL, et al. (2008) An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res 68: 6084-91.
54. Oda K, Stokoe D, Taketani Y, McCormick F, (2005) High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. Cancer Res 65: 10669-73.
55. Balsara BR, Testa JR, (2002) Chromosomal imbalances in human lung cancer. Oncogene 21: 6877-83.
56. Garnis C, Lockwood WW, Vucic E, Ge Y, Girard L, et al. (2006) High-resolution analysis of non-small cell lung cancer cell lines by whole genome tiling path array CGH. Int J Cancer 118: 1556-64.
57. Bouchard C, Thieke K, Maier A, Saffrich R, Hanley-Hyde J, et al. (1999) Direct induction of cyclin D2 by Myc contributes to cell cycle progression and sequestration of p27. EMBO J 18: 5321-33.